Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

SASAKI MEDICAL LLC

NPI: 1326490475 · ROSEVILLE, MN 55113 · Multi-Specialty Clinic/Center · NPI assigned 07/12/2016

$24.05M
Total Medicaid Paid
233,567
Total Claims
154,868
Beneficiaries
22
Codes Billed
2018-04
First Month
2024-12
Last Month

Provider Details

Authorized OfficialSASAKI, ALANA (PRESIDENT)
NPI Enumeration Date07/12/2016

Related Entities

Other providers sharing the same authorized official: SASAKI, ALANA

ProviderCityStateTotal Paid
SASAKI MEDICAL LLC ST PAUL MN $342K

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 968 $37K
2019 18,698 $1.97M
2020 31,302 $4.04M
2021 41,607 $5.05M
2022 42,727 $4.37M
2023 56,774 $4.97M
2024 41,491 $3.61M

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 74,349 44,084 $7.33M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 62,632 38,856 $3.47M
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 27,478 20,512 $2.69M
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 18,692 14,823 $2.57M
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 10,103 6,988 $2.54M
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 8,539 6,545 $1.72M
99205 Prolong outpt/office vis 7,664 6,898 $1.31M
99215 Prolong outpt/office vis 9,771 4,636 $1.26M
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 2,737 2,607 $314K
96131 1,292 1,247 $178K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 2,287 2,023 $142K
90837 Psychotherapy, 53 minutes with patient 1,336 690 $138K
96130 1,302 1,258 $125K
96137 860 834 $92K
H0001 Alcohol and/or drug assessment 155 149 $36K
80305 2,656 1,094 $32K
96139 286 272 $32K
96136 859 833 $31K
90832 Psychotherapy, 30 minutes with patient 190 162 $11K
96138 286 272 $8K
90834 Psychotherapy, 45 minutes with patient 60 56 $5K
90791 Psychiatric diagnostic evaluation 33 29 $4K